The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
Official Title: Prospective Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
Study ID: NCT02817178
Brief Summary: The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses. The investigators found high frequency of naturally occuring UCP-specific TH1 cells in long term survival of metastatic colorectal cancer (CRC) previously treated by 5 fluoro-uracil -oxaliplatin (Folfox) +/- bevacizumab regiment (Godet et al. OncoImmunology 2012 and unpublished data). Epitopes-CRC02 is a French prospective multicenter study which will evaluate the post chemotherapy and post surgery modulation of host tumor-specific CD4 TH1 cell responses in metastatic colorectal cancer patients and their correlation with progression-free survival.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Hospitalier Régional Universitaire de Besançon, Besançon, , France
Polyclinique de Franche-Comté, Besançon, , France
Hôpitaux Civils de Colmar, Colmar, , France
Centre Georges François Leclerc, Dijon, , France
Hôpital Nord Franche-Comté, Montbéliard, , France
Institut de Cancérologie de Lorraine, Nancy, , France
Hôpital Européen Georges Pompidou, Paris, , France
Centre Paul Strauss, Strasbourg, , France
Centre Hospitalier Universitaire de Tours, Tours, , France
Name: Stefano KIM, Dr
Affiliation: CHU de Besancon
Role: PRINCIPAL_INVESTIGATOR